<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article156</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/VEST" style="display:block; margin-bottom:10px;">VEST Original</a></li>
<h2><strong>VEST</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Wearable Cardioverter-Defibrillator after Myocardial Infarction"<br/>
The New England Journal of Medicine. <br/>
Article DOI: N/A<br/>
ClinicalTrials.gov number, NCT01446965.<br/>
PubMed - Full text - PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcomes<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Among patients with recent myocardial infarction and an ejection fraction of 35% or less, does a wearable cardioverter–defibrillator reduce the incidence of sudden death during the high-risk period before an implantable cardioverter-defibrillator (ICD) is indicated?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with a recent myocardial infarction and an ejection fraction of 35% or less, the wearable cardioverter–defibrillator did not significantly reduce the primary outcome of arrhythmic death compared with guideline-directed medical therapy alone during the first 90 days post-infarction.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the last knowledge update for this summary, there were no specific guideline recommendations reflecting the trial's results regarding the wearable cardioverter–defibrillator post-myocardial infarction.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, randomized, controlled trial.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
2302 participants with acute myocardial infarction and an ejection fraction of 35% or less.<br/>
<br/>
Inclusion Criteria<br/>
- Hospitalized with an acute myocardial infarction<br/>
- Ejection fraction of 35% or less assessed ≥8 hours after myocardial infarction or ≥48 hours after coronary-artery bypass grafting<br/>
<br/>
Exclusion Criteria<br/>
- Implanted cardioverter–defibrillator or unipolar pacemaker<br/>
- Significant valve disease, long-term hemodialysis, inappropriate chest circumference for the device, pregnancy, or extended nursing facility stay<br/>
<br/>
Baseline Characteristics<br/>
- Mean ejection fraction: 28%<br/>
- Majority underwent PCI during index_gpt hospitalization<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Participants randomized 2:1 to wearable cardioverter–defibrillator plus guideline-directed therapy or guideline-directed therapy alone.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes<br/>
- Composite of sudden death or death from ventricular tachyarrhythmia at 90 days (arrhythmic death)<br/>
<br/>
Secondary Outcomes<br/>
- Death from any cause<br/>
- Nonarrhythmic death<br/>
- Hospitalization for various cardiac conditions<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Misclassification of the adjudicated cause of death may have reduced power for the primary outcome.<br/>
- Device adherence less than anticipated, potentially diminishing the power to show the wearable cardioverter–defibrillator's effectiveness.<br/>
- Primary endpoint was changed from all-cause mortality at 60 days to arrhythmic death at 90 days.<br/>
- Continued funding by device manufacturer could introduce potential bias.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
National Institutes of Health and Zoll Medical. Zoll Medical had no role in trial design, data analysis, or publication decisions but did participate in site monitoring.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Full text of the original article at NEJM.org.<br/>
- ClinicalTrials.gov identifier: NCT01446965.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
